Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytokine network in human multiple myeloma.

B Klein1, R Bataille

  • 1Laboratory of Immuno-hématologic Oncology, Hôtel-Dieu, Nantes, France.

Hematology/Oncology Clinics of North America
|April 1, 1992
PubMed
Summary

Interleukin-6 (IL-6) drives multiple myeloma growth and aggressiveness, impacting patient prognosis. Targeting IL-6 offers a promising therapeutic strategy for this hematologic malignancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical simulation of vertical cavity surface emitting lasers.

Optics express·2009
Same author

[Colonic perforation after extracorporeal shock wave lithotripsy].

Deutsche medizinische Wochenschrift (1946)·2009
Same author

Thyroid surgery in Burkina Faso, West Africa: experience from a surgical help program.

World journal of surgery·2008
Same author

[Oocyte and embryo quality: do the apoptotic markers have a place in the preimplantation genetic diagnostic?].

Gynecologie, obstetrique & fertilite·2008
Same author

[Could apoptotic markers help the exploration of male infertility?].

Gynecologie, obstetrique & fertilite·2008
Same author

ETV6 mutations and loss in AML-M0.

Leukemia·2008

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Elevated Interleukin-6 (IL-6) levels are observed in 37% of multiple myeloma (MM) patients at diagnosis.
  • High IL-6 is linked to increased disease aggressiveness, myeloma cell proliferation, and poorer patient outcomes.
  • IL-6 is primarily produced by the tumor microenvironment, not myeloma cells themselves.

Purpose of the Study:

  • To investigate the role of IL-6 and other cytokines in multiple myeloma cell proliferation.
  • To explore the therapeutic potential of targeting IL-6 in MM treatment.

Main Methods:

  • Establishing IL-6-dependent myeloma cell lines in vitro.
  • Evaluating the effects of anti-IL-6 therapies on myeloma cell proliferation in vivo.
  • Assessing the synergistic effects of hematopoietic cytokines (GM-CSF, IL-3, IL-5, G-CSF) with IL-6.
  • Investigating the impact of Interferon-alpha (IFN-alpha), Tumor Necrosis Factor (TNF), and Interferon-gamma (IFN-gamma) on IL-6-mediated myeloma cell growth.

Main Results:

  • IL-6 acts as a significant growth factor for malignant plasmablastic cells.
  • Anti-IL-6 therapies effectively inhibit myeloma cell proliferation in patients with advanced disease.
  • Hematopoietic cytokines synergize with IL-6 to promote myeloma cell proliferation.
  • IFN-alpha and TNF induce autocrine IL-6 production, enabling autonomous cell growth, while IFN-gamma inhibits IL-6-mediated proliferation.

Conclusions:

  • Cytokines, particularly IL-6, play a critical role in regulating the multiple myeloma clone.
  • Understanding these cytokine interactions has direct implications for developing targeted MM therapies.
  • Targeting IL-6 and related cytokine pathways represents a viable therapeutic strategy for multiple myeloma.

Related Experiment Videos